Starting TRT: A Decision Framework for Veterans

Testosterone replacement therapy (TRT) is a prescribed medical treatment intended to restore physiological testosterone levels in patients with a confirmed clinical deficiency. This therapy is not a routine strategy for improving athletic performance or slowing the natural aging process. It is a specific clinical intervention for a defined medical condition. A proper evaluation requires finding a reversible cause before committing to long term hormone replacement. The central decision for veterans is whether expected clinical benefits justify the continuous monitoring requirements and potential health risks.

Hormones And Health

The endocrine system regulates everything from muscle protein synthesis to red blood cell production. Testosterone plays a central role in maintaining lean tissue mass and supporting overall metabolic health. Physical performance and long term health are directly linked through these vital hormonal pathways. Adequate testosterone helps the body adapt to physical stress and repair cellular damage after heavy exertion. When this system functions properly, physical capability remains stable over time.

I remember waking up after a poor night of sleep and realizing that my training recovery was taking much longer than it used to. I realized that readiness is more than just pushing through the fatigue. It requires a dedicated approach to sleep and hormonal health, which completely shifted how I view long term capability. Without proper rest and endocrine support, even the most intense training programs will fail to produce positive physical adaptations.

If a veteran struggles with fatigue, the problem might not be an isolated hormone deficiency. Sleep apnea, post-traumatic stress, and chronic pain can suppress natural hormone production. These foundational recovery systems must be evaluated before jumping straight to a pharmacological solution.

Defining Normal Levels

The American Urological Association uses a total testosterone level below 300 ng/dL as a reasonable diagnostic threshold. A clinical diagnosis requires confirming this laboratory result with two separate early morning measurements. The clinician must also identify physical symptoms or signs that are consistent with clinical hypogonadism. Low laboratory values alone do not justify starting a lifetime medical treatment.

The goal of treatment is to restore testosterone to a normal physiological baseline. The American Urological Association recommends adjusting the treatment dose to reach the middle tertile of the normal reference range. This approach prioritizes symptom resolution over creating a supraphysiologic hormone level for performance enhancement. The U.S. Food and Drug Administration approves testosterone products for men with associated medical conditions.

Veterans carry unique occupational histories that require careful clinical evaluation. VA research reporting has found that men and women who reported environmental, chemical, or hazardous exposures during military service had increased rates of infertility. This association does not automatically establish that low testosterone is the root cause of an individual veteran's specific symptoms. A clinician must investigate whether the primary issue is testicular or related to the hypothalamus.

Before starting therapy, the patient and clinician should identify what specific improvement would count as a clinical success. Meaningful improvements might include better morning erections, increased sexual desire, or the correction of clinically significant anemia. Vague goals like feeling stronger are nonspecific and might not improve with hormonal treatment alone. The goal is restoring health rather than pursuing general athletic performance through medication.

Choosing A Formulation

The U.S. Food and Drug Administration recognizes several approved testosterone formulations. Approved options include topical gels, transdermal patches, buccal systems, and injections. The best choice depends on treatment goals, medication cost, and the patient's lifestyle.

Injectable testosterone is often convenient and generally costs less than other administration methods. However, some injection schedules produce noticeable peaks and troughs in hormone levels. Patients might experience mood changes or energy fluctuations as their blood levels rise and fall between scheduled doses. Injection technique, needle access, and follow-up logistics also matter greatly for deployed personnel who travel between locations.

Topical gels and creams provide steadier hormone exposure for some patients. The American Urological Association advises clinicians to discuss the risk of testosterone transfer when prescribing topical products. Transferring the hormone to a partner or a child is a serious household safety concern. Patients must wash their hands and cover the application site until the product has dried.

Patches and buccal products offer alternative delivery methods for patients who dislike injections or gels. However, these systems can cause localized skin irritation and other administrative complications. The American Urological Association advises against prescribing alkylated oral testosterone due to safety concerns. The organization recommends using commercially manufactured products rather than compounded alternatives whenever possible.

Monitoring The Treatment

Hormone replacement is not a simple automated process that patients can ignore after the first dose. The American Urological Association recommends checking blood levels after an appropriate initial interval to confirm the target dose. Patients then require continuous testosterone testing every 6 to 12 months while the therapy continues. This consistent monitoring ensures that the patient stays within a safe physiological range.

Routine blood tests must track hemoglobin and hematocrit levels. Exogenous testosterone can increase red blood cell production, which thickens the blood over time. Clinicians must also monitor blood pressure, prostate health, and potential mood changes. The timing of the blood test must align with the specific formulation being used to provide an accurate clinical reading.

Cardiovascular safety evidence has evolved in recent years. In February 2025, the U.S. Food and Drug Administration removed boxed warning language regarding cardiovascular outcomes after reviewing the TRAVERSE trial. However, the agency retained the limitation for age related hypogonadism and added specific blood pressure warnings. The TRAVERSE trial found no increase in adverse cardiovascular outcomes among men using testosterone for hypogonadism.

This regulatory change highlights the ongoing importance of strict blood pressure monitoring. It does not prove that hormone therapy improves longevity or general health in men without confirmed hypogonadism.

Fertility And Service

Fertility preservation is a critical conversation for active duty personnel and younger veterans. Exogenous testosterone suppresses the hormonal signals that stimulate normal sperm production. A patient might feel better physically while their actual reproductive capacity steadily declines. Symptom improvement is not evidence that fertility has been preserved.

The American Urological Association states that exogenous testosterone should not be prescribed to men who are currently trying to conceive. The guideline recommends a reproductive health evaluation for any man interested in future fertility. Specialists might use human chorionic gonadotropin or selective estrogen receptor modulators to maintain sperm production. These alternatives require expert supervision and are not appropriate for every single patient.

Veterans must tell their prescribing clinician if they want children in the future. A baseline semen analysis can help establish reproductive health before the first hormone dose. Ignoring this step before starting testosterone and hormone protocols can lead to permanent reproductive complications down the road.

Evaluating Readiness Risk

Military screening for hormone deficiency remains a debated topic across the medical community. The American Association of Clinical Endocrinology stated that current evidence does not support routine population screening of asymptomatic men. A report on Department of Defense policy noted concerns that broad screening could encourage unnecessary medical overtreatment. A low screening result should never become an automatic prescription without compatible physical symptoms.

Treatment can also impact physical readiness and injury risk for active duty personnel. A recent active duty study reported associations between testosterone replacement and tendon rupture alongside earlier rupture. The study in Military Medicine also noted associations with carpal tunnel syndrome and trigger finger. Medical providers should discuss these findings in the context of a service member's training load and prior injury history.

Reassessing The Benefit

A normal blood test result does not automatically equal a successful treatment outcome. The American Urological Association recommends discussing treatment cessation if symptoms do not improve after 3 to 6 months. This trial based framework prevents patients from taking unnecessary medications indefinitely.

Veterans should define their specific symptoms before starting the treatment. If the target symptoms do not improve after blood levels normalize, increasing the dose is rarely the correct answer. The clinician must investigate other potential causes like sleep apnea, thyroid disease, or cardiometabolic illness.

Many underlying health conditions can produce symptoms that closely mimic a true hormone deficiency. Treating clinical obesity, addressing poor sleep quality, and managing systemic illness can restore normal function naturally. A veteran should be wary of any medical clinic that offers hormone therapy after a single borderline test without investigating other causes. True healthcare requires a comprehensive clinical evaluation rather than a quick prescription fix.

Consult Your Provider

The information provided in this article is for educational purposes and does not replace professional medical advice. Veterans and former service members should consult a qualified physician or VA healthcare provider before seeking hormone testing or self diagnosing a deficiency. Only a licensed medical professional can safely evaluate symptoms and prescribe appropriate clinical treatments.

The Bottom Line

The key takeaway is that testosterone replacement is a lifelong medical commitment requiring strict clinical justification, continuous blood monitoring, and a willingness to stop treatment if specific symptoms do not improve.

Sources

1. Testosterone Replacement Therapy and Heart Disease
2. TRAVERSE found cardiovascular noninferiority—not a longevity benefit
3. FDA's 2026 testosterone replacement therapy label ...
4. Functional causes of low testosterone predominate in contemporary Australian endocrine referral practice: a two centre experience across 5 years